1 Answers
Newly diagnosed glioblastoma multiforme: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1 of a 28-day cycle of Temozolomide for 6 cycles
Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle.
The recommended dose for Temozolomide as an intravenous infusion over 90 minutes is the same as the dose for the oral capsule formulation. Bioequivalence has been established only when Temozolomide for Injection was given over 90 minutes
Should be taken on an empty stomach. Take at least 1 hr before meals.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Geriatric Use: Clinical studies of temozolomide did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Renal Impairment: Caution should be exercised when temozolomide is administered to patients with severe renal impairment
Hepatic Impairment: Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment
টেমনিক্স ক্যাপসুল সম্পর্কে বিস্তারিত জেনে নিন এই লিঙ্ক থেকে টেমনিক্স